NCT02662452View on ClinicalTrials.gov

First-in-Human Single and Multiple Dose of GLPG2222

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Healthy
Interventions
DRUG

GLPG2222 single dose

single ascending doses, oral suspension

DRUG

Placebo single dose

single doses, oral suspension, matching placebo

DRUG

GLPG2222 multiple doses

multiple ascending doses, daily for 14 days, oral suspension

DRUG

Placebo multiple doses

multiple doses, daily for 14 days, oral suspension, matching placebo

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT02662452 - First-in-Human Single and Multiple Dose of GLPG2222 | Biotech Hunter | Biotech Hunter